Cantor Fitzgerald Assumes Harpoon Therapeutics (HARP) at Overweight

May 13, 2022 2:43 PM EDT
Get Alerts HARP Hot Sheet
Price: $2.55 -3.04%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 4 | Down: 15 | New: 18
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Jennifer Kim assumes coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Overweight rating and a price target of $15.00 (from $33.00).

The analyst commented, "HARP is a clinical-stage IO company focused on developing a novel class of T cell engagers (engineered proteins that direct a patient's own T cells to kill specific tumor antigen-expressing cells) for solid tumors and hematologic malignancies. In-house, HARP has developed three proprietary technology platforms (TriTAC, ProTriTAC, TriTAC-XR) to discover and develop product candidates. The company's clinical-stage pipeline currently includes three TriTAC-based product candidates in Phase 1/2 development: 1) HPN328 (DLL3-targeting) for small cell lung cancer (SCLC) and other DLL3-expressing tumors; 2) HPN217 (BCMA-targeting) for multiple myeloma (MM); and 3) HPN536 (mesothelin [MSLN]-targeting) for ovarian, pancreatic, and other MSLN-associated solid tumors. All three programs are expected to complete dose-escalation this year, with dose-expansion cohorts for HPN217 and HPN328 guided to initiate in 2022. HARP is also advancing its lead ProTriTAC candidate HPN601 (EpCAM-targeting), with IND submission expected in 2H22, and is expected to advance its first TriTAC-XR candidate into IND enabling studies by the end of 2022. HARP reported cash, cash equivalents and marketable securities of $112.5MM as of 3/31/22, which the company expects can fund operations through 1H23."

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $1.86 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Cantor Fitzgerald